Exelixis(EXEL) - 2025 Q1 - Quarterly Results

Exhibit 99.1 Contacts: Chris Senner Chief Financial Officer Exelixis, Inc. 650-837-7240 csenner@exelixis.com Susan Hubbard EVP, Public Affairs & Investor Relations Exelixis, Inc. 650-837-8194 shubbard@exelixis.com Exelixis Announces First Quarter 2025 Financial Results and Provides Corporate Update - Total Revenues of $555.4 million, Cabozantinib Franchise U.S. Net Product Revenues of$513.3 million - - GAAP Diluted EPS of $0.55, Non-GAAP Diluted EPS of$0.62 - - Increasing 2025 Full Year Net Product Revenu ...